Loading
TNG462 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).
TNG462 is a small-molecule drug developed by Tango Therapeutics and Servier Bio-Innovation. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion. ClinicalTrials.gov describes the intervention as: TNG462, a selective PRMT5 inhibitor, will be administered orally. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT05732831, plans to enrol 225 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion. Connects to PRMT5 (MTAP-deleted cancers).
1.TNG462 slips into a pocket on PRMT5 (MTAP-deleted cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TNG462" OR ABSTRACT:"TNG462") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TNG462, not a curated reading list.
Shares Tango Therapeutics, PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.